<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(2)</volume><submitter>Xiong Q</submitter><pubmed_abstract>Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (&lt;i>n&lt;/i> = 8) demonstrated a high level of correlation with the PDX (&lt;i>n&lt;/i> = 2) and clinical response in patients (&lt;i>n&lt;/i> = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.</pubmed_abstract><journal>Bioengineering &amp; translational medicine</journal><pagination>e10624</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10905551</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response.</pubmed_title><pmcid>PMC10905551</pmcid><pubmed_authors>Zeng S</pubmed_authors><pubmed_authors>Fan W</pubmed_authors><pubmed_authors>Lin T</pubmed_authors><pubmed_authors>Xiong Q</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Gao H</pubmed_authors><pubmed_authors>Liu T</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Wei Q</pubmed_authors><pubmed_authors>Ge Y</pubmed_authors><pubmed_authors>Ying Y</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Yu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response.</name><description>Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (&lt;i>n&lt;/i> = 8) demonstrated a high level of correlation with the PDX (&lt;i>n&lt;/i> = 2) and clinical response in patients (&lt;i>n&lt;/i> = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-18T17:15:52.793Z</modification><creation>2025-04-07T04:46:46.556Z</creation></dates><accession>S-EPMC10905551</accession><cross_references><pubmed>38435820</pubmed><doi>10.1002/btm2.10624</doi></cross_references></HashMap>